safoof triphala and ravghan-i-gul in diabetic neuropathy

Evaluation of the Efficacy of Triphala and Ravghan-i-Gul in Controlling the Progress of Diabetic Neuropathy: An Interventional Study - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099146

Enrollment

Registered

2025-12-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: single arm open label: powder of triphala(halela, balela,aamla) 6 g twice daily will be given orally and ravghan-i-gul 10 ml twice daily will be given for local application Control Inte

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients of either gender 2)Patients of 30 years and above 3)Patient having Diabetes Mellitus with burning sensation and tingling sensation etc

Exclusion criteria

Exclusion criteria: 1)Pregnancy and lactation 2)Any localized skin lesion over the legs (where integrity of skin is compromised) 3)Unwillingness or inability to comply with the requirements of the protocol

Design outcomes

Primary

Measure	Time frame
changes in scoring ofMichigan neuropathy screening instrument (MNSI) and Vibration perception threshold (VPT) Timepoint: at baseline(0th day) and 60th day	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactAbdul Haseeb Ansari

National Institute of Unani Medicine

ahansari001@gmail.com9448258140

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026